Galapagos Announces Phase 3 Results for GLPG3667
Galapagos (GLPG) announced the topline results from two Phase 3-enabling studies evaluating the efficacy and safety of GLPG3667, a selective TYK2 inhibitor, in patients with dermatomyositis and active systemic lupus erythematosus. The GALARISSO DM study met its primary endpoint, showing that GLPG3667, administered once daily at 150 mg in addition to standard-of-care therapy, achieved a statistically significant clinical benefit in the Total Improvement Score at Week 24, compared to placebo. The pre-specified threshold of statistical significance was set at 10%. GLPG3667 also showed meaningful clinical improvements compared to placebo on several secondary endpoints of disease activity, including TIS20, TIS40, TIS60 and m-CDASI-A2. GLPG3667 demonstrated a favorable safety and tolerability profile throughout the 24-week treatment period. In the GALACELA SLE study, GLPG3667, administered once daily at 75 mg and 150 mg in addition to standard-of-care therapy, the primary endpoint analysis of dose-response on SLE responder index -4 at Week 32 did not meet statistical significance. However, GLPG3667 showed numerical improvements over placebo on several secondary endpoints, particularly on skin-related outcomes. The safety profile was consistent with previous studies with GLPG3667. The GALACELA study is currently ongoing, and the final Week 48 data, expected in the second quarter of 2026, will be essential to assess the totality of the evidence and determine potential next steps for the SLE program. The company aims to present data at an upcoming medical conference. Gilead (GILD) agreed to temporarily waive certain rights under the 10-year global option, license and collaboration agreement between Galapagos and Gilead, enabling Galapagos to pursue external partnership opportunities for GLPG3667.
Trade with 70% Backtested Accuracy
Analyst Views on GILD
About GILD
About the author
Pharma Stocks on the Verge of a Breakthrough: Earnings May Propel Them Forward.
- Pharmaceutical Stocks Performance: Pharmaceutical stocks have recently reached new highs in the market.
- Earnings Potential: Upcoming earnings reports are expected to further boost the stock prices of pharmaceutical companies.
Trump Administration Launches Medicare Drug Price Negotiations
- Expansion of Drug Negotiations: The Trump administration has expanded Medicare drug price negotiations to include treatments administered in doctors' offices for conditions such as diabetes and HIV, affecting 15 drugs set to take effect in 2028, aiming to reduce out-of-pocket costs for beneficiaries.
- Spending Overview: According to the Centers for Medicare and Medicaid Services, approximately 1.8 million beneficiaries utilized these medications between 2024 and 2025, accounting for about $27 billion in spending, highlighting the significance of Medicare expenditures in drug price negotiations.
- Pharmaceutical Impact Assessment: Analysts indicate that for 14 of the drugs, only Gilead's Biktarvy significantly impacts the company's estimated 2027 global sales, representing around 8%, while other drugs' Medicare revenue exposure is limited to 0% to 3%, suggesting minimal overall revenue impact for pharmaceutical companies.
- Kaiser Settlement on Fraud: Kaiser Permanente has agreed to a historic $556 million settlement over Medicare Advantage fraud allegations, reflecting the government's stringent enforcement stance on Medicare fraud, which could have far-reaching implications for the industry.
